Advertisement

Safety and efficacy of a novel silver-impregnated urinary catheter system for preventing catheter-associated bacteriuria: A pilot randomized clinical trial

      Highlights

      • We present a pilot randomized controlled trial to evaluate a novel Foley catheter.
      • Novel silver catheter system includes an antimicrobial matrix and antireflux valve.
      • Test system was tolerated and seemingly effective in preventing bacteriuria.
      • Test system seemed especially effective against gram-negative bacilli.
      • A pivotal study is warranted.

      Background

      The purpose of this study was to evaluate the safety of a novel silver-impregnated Foley catheter system designed to prevent catheter-associated bacteriuria and funguria, assess recruitment feasibility for a future pivotal trial, and preliminarily assess efficacy.

      Methods

      This single-center, randomized controlled trial at a university hospital involved adult neurosurgical patients expected to have a urinary catheter for ≥24 hours. Subjects were randomized to a novel silver-impregnated (test) Foley catheter system or a control system. They were followed for 30 days (or until discharge) while catheterized and for up to 48 hours after catheter removal, with daily bacteriuria testing and assessment for symptoms of infection and catheter intolerance.

      Results

      Ninety-five subjects were randomized (intention-to-treat [ITT] population). Of these, 61 subjects (64%) had a catheter for ≥24 hours without perioperative antibiotics beyond 24 hours (evaluable population). In the ITT population, 11 of 95 (12%) subjects had an asymptomatic bacteriuria (ABU) event. Compared with controls, test system recipients had a trend toward longer time to ABU in the ITT population (P = .08, log-rank test) and a longer time to ABU in the evaluable population (P = .03). All 6 ABU events caused by gram-negative bacilli occurred in the control group.

      Conclusion

      In this pilot randomized trial the test system was well tolerated and seemingly effective in preventing catheter-associated bacteriuria, especially with gram-negative bacilli. A pivotal study is warranted.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Infection Control
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Saint S.
        • Wiese J.
        • Amory J.K.
        • Bernstein M.L.
        • Patel U.D.
        • Zemencuk J.K.
        • et al.
        Are physicians aware of which of their patients have indwelling urinary catheters?.
        Am J Med. 2000; 109: 476-480
        • Weinstein J.W.
        • Mazon D.
        • Pantelick E.
        • Reagan-Cirincione P.
        • Dembry L.M.
        • Hierholzer Jr., W.J.
        A decade of prevalence surveys in a tertiary-care center: trends in nosocomial infection rates, device utilization, and patient acuity.
        Infect Control Hosp Epidemiol. 1999; 20: 543-548
        • Krieger J.N.
        • Kaiser D.L.
        • Wenzel R.P.
        Urinary tract etiology of bloodstream infections in hospitalized patients.
        J Infect Dis. 1983; 148: 57-62
        • Tambyah P.A.
        • Maki D.G.
        Catheter-associated urinary tract infection is rarely symptomatic: a prospective study of 1,497 catheterized patients.
        Arch Intern Med. 2000; 160: 678-682
        • Saint S.
        Clinical and economic consequences of nosocomial catheter-related bacteriuria.
        Am J Infect Control. 2000; 28: 68-75
        • Maki D.G.
        • Tambyah P.A.
        Engineering out the risk for infection with urinary catheters.
        Emerg Infect Dis. 2001; 7: 342-347
        • Stark R.P.
        • Maki D.G.
        Bacteriuria in the catheterized patient. What quantitative level of bacteriuria is relevant?.
        N Engl J Med. 1984; 311: 560-564
      1. Scott RD II. The direct medical costs of healthcare-associated infections in U.S. hospitals and the benefits of prevention. 2009. Available from: http://www.cdc.gov/hai/pdfs/hai/scott_costpaper.pdf. Accessed December 1, 2014.

        • Jarvis W.R.
        Selected aspects of the socioeconomic impact of nosocomial infections: morbidity, mortality, cost, and prevention.
        Infect Control Hosp Epidemiol. 1996; 17: 552-557
        • Cope M.
        • Cevallos M.E.
        • Cadle R.M.
        • Darouiche R.O.
        • Musher D.M.
        • Trautner B.W.
        Inappropriate treatment of catheter-associated asymptomatic bacteriuria in a tertiary care hospital.
        Clin Infect Dis. 2009; 48: 1182-1188
        • Trautner B.W.
        Management of catheter-associated urinary tract infection.
        Curr Opin Infect Dis. 2010; 23: 76-82
        • Saint S.
        • Meddings J.A.
        • Calfee D.
        • Kowalski C.P.
        • Krein S.L.
        Catheter-associated urinary tract infection and the Medicare rule changes.
        Ann Intern Med. 2009; 150: 877-884
        • Lo E.
        • Nicolle L.
        • Classen D.
        • Arias K.M.
        • Podgorny K.
        • Anderson D.J.
        • et al.
        Strategies to prevent catheter-associated urinary tract infections in acute care hospitals.
        Infect Control Hosp Epidemiol. 2008; 29: S41-S50
        • Tambyah P.A.
        • Halvorson K.T.
        • Maki D.G.
        A prospective study of pathogenesis of catheter-associated urinary tract infections.
        Mayo Clin Proc. 1999; 74: 131-136
        • Burke J.
        • Riley D.
        Nosocomial urinary tract infection.
        in: Mayhall C.G. Hospital epidemiology and infection control. Lippincott Williams and Wilkins, Baltimore [MD]1996: 139-153
        • Stamm W.E.
        Catheter-associated urinary tract infections: epidemiology, pathogenesis, and prevention.
        Am J Med. 1991; 91: 65S-71S
        • Chopra I.
        The increasing use of silver-based products as antimicrobial agents: a useful development or a cause for concern?.
        J Antimicrob Chemother. 2007; 59: 587-590
        • Sardi J.C.
        • Scorzoni L.
        • Bernardi T.
        • Fusco-Almeida A.M.
        • Mendes Giannini M.J.
        Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options.
        J Med Microbiol. 2013; 62: 10-24
        • Drekonja D.M.
        • Kuskowski M.A.
        • Wilt T.J.
        • Johnson J.R.
        Antimicrobial urinary catheters: a systematic review.
        Expert Rev Med Devices. 2008; 5: 495-506
        • Johnson J.R.
        • Kuskowski M.A.
        • Wilt T.J.
        Systematic review: antimicrobial urinary catheters to prevent catheter-associated urinary tract infection in hospitalized patients.
        Ann Intern Med. 2006; 144: 116-126
        • Srinivasan A.
        • Karchmer T.
        • Richards A.
        • Song X.
        • Perl T.M.
        • et al.
        A prospective trial of a novel, silicone-based, silver-coated foley catheter for the prevention of nosocomial urinary tract infections.
        Infect Control Hosp Epidemiol. 2006; 27: 38-43
        • Pickard R.
        • Lam T.
        • MacLennan G.
        • Starr K.
        • Kilonzo M.
        • McPherson G.
        • et al.
        Antimicrobial catheters for reduction of symptomatic urinary tract infection in adults requiring short-term catheterisation in hospital: a multicentre randomised controlled trial.
        Lancet. 2012; 380: 1927-1935
        • Lederer J.W.
        • Jarvis W.R.
        • Thomas L.
        • Ritter J.
        Multicenter cohort study to Assess the impact of a Silver-Alloy and hydrogel-coated urinary catheter on symptomatic catheter-associated urinary tract infections.
        J Wound Ostomy Continence Nurs. 2014; 41: 473-480
        • Lee S.J.
        • Kim S.W.
        • Cho Y.H.
        • Shin W.S.
        • Lee S.E.
        • Kim C.S.
        • et al.
        A comparative multicentre study on the incidence of catheter-associated urinary tract infection between nitrofurazone-coated and silicone catheters.
        Int J Antimicrob Agents. 2004; 24: S65-S69
        • Wald H.L.
        • Kramer A.M.
        Feasibility of audit and feedback to reduce postoperative urinary catheter duration.
        J Hosp Med. 2011; 6: 183-189
        • Johnson J.R.
        • Johnston B.
        • Kuskowski M.A.
        In vitro comparison of nitrofurazone- and silver alloy-coated foley catheters for contact-dependent and diffusible inhibition of urinary tract infection-associated microorganisms.
        Antimicrobial Agents Chemother. 2012; 56: 4969-4972
        • Maki D.G.
        • Knasinski V.
        • Halvorson K.
        • Tambyah P.A.
        A novel silver-hydrogel impregnated indwelling catheter reduces CAUTIs: a prospective double-blind trial (abstract).
        Infect Control Hosp Epidemiol. 1998; 19: 680
        • Ip M.
        • Lui S.L.
        • Poon V.K.
        • Lung I.
        • Burd A.
        • et al.
        Antimicrobial activities of silver dressings: an in vitro comparison.
        J Med Microbiol. 2006; 55: 59-63
        • Eykyn S.J.
        Urinary tract infections in the elderly.
        Br J Urol. 1998; 82: 79-84